HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Qiang Xia Selected Research

norbinaltorphimine

8/2010[The study of effects and mechanism of U50, 488H on electrical coupling during ischemia in the perfused isolated rat heart].
8/2009[Mito K(ATP) and kappa-opioid receptor mediate the neuroprotective effect of limb ischemic post-conditioning on rat brain ischemia/reperfusion injury].
9/2006Kappa-opioid receptors mediate cardioprotection by remote preconditioning.
2/2006[Delayed electrical uncoupling is involved in kappa-opioid receptor activation -induced cardioprotective effect in the isolated rat heart].
12/2005Delayed uncoupling is related to cardioprotection induced by kappa-agonist U-50,488H in rat heart.
1/2005The Effects of κ-Opioid Receptor Stimulation on Electrical Coupling during Ischemia in the Perfused Isolated Rat Heart.
5/2004Cardioprotection of interleukin-2 is mediated via kappa-opioid receptors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Qiang Xia Research Topics

Disease

56Hepatocellular Carcinoma (Hepatoma)
09/2022 - 12/2007
53Neoplasms (Cancer)
09/2022 - 08/2004
51Ischemia
01/2022 - 01/2002
48Reperfusion Injury
01/2022 - 01/2002
21Infarction (Infarctions)
06/2013 - 01/2002
18Infections
07/2021 - 03/2010
17Liver Diseases (Liver Disease)
01/2022 - 09/2013
13Carcinogenesis
06/2022 - 08/2004
12Liver Neoplasms (Liver Cancer)
06/2022 - 07/2012
12Neoplasm Metastasis (Metastasis)
01/2021 - 08/2008
12Cholangiocarcinoma
01/2021 - 11/2017
12Hypoxia (Hypoxemia)
04/2019 - 01/2003
11Inflammation (Inflammations)
10/2022 - 01/2010
11Biliary Atresia
06/2021 - 06/2012
11Liver Cirrhosis (Hepatic Cirrhosis)
01/2020 - 11/2010
9Myocardial Ischemia (Ischemic Heart Diseases)
03/2014 - 01/2002
8End Stage Liver Disease
07/2022 - 11/2009
8Myocardial Infarction
07/2017 - 01/2005
8Brain Ischemia (Cerebral Ischemia)
01/2013 - 05/2006
7Necrosis
03/2022 - 04/2011
7Cardiac Arrhythmias (Arrythmia)
02/2009 - 01/2002
6Hepatitis B
08/2021 - 11/2009
6Lymphatic Metastasis
08/2021 - 07/2016
6Carcinoma (Carcinomatosis)
11/2018 - 08/2004
5HIV Infections (HIV Infection)
03/2022 - 03/2013
5Hemorrhage
01/2020 - 08/2010
5Acquired Immunodeficiency Syndrome (AIDS)
01/2019 - 09/2014
5Heart Failure
08/2016 - 01/2005
5Septic Shock (Toxic Shock Syndrome)
01/2012 - 01/2005
4Hypertension (High Blood Pressure)
01/2021 - 07/2007
4Hepatitis
01/2021 - 01/2019
4Bacterial Infections (Bacterial Infection)
01/2020 - 12/2011
4Fibrosis (Cirrhosis)
01/2020 - 01/2016
3Breast Neoplasms (Breast Cancer)
01/2022 - 08/2004
3Acute Kidney Injury (Acute Renal Failure)
01/2022 - 06/2012
3Non-alcoholic Fatty Liver Disease
01/2021 - 01/2019
3Sepsis (Septicemia)
12/2020 - 12/2003
3Acute Liver Failure (Fulminant Hepatic Failure)
10/2020 - 05/2014

Drug/Important Bio-Agent (IBA)

20Proteins (Proteins, Gene)FDA Link
01/2021 - 01/2003
16L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
06/2013 - 05/2004
13Biomarkers (Surrogate Marker)IBA
03/2022 - 06/2012
12Biological ProductsIBA
10/2022 - 08/2004
11Mitochondrial Permeability Transition PoreIBA
03/2014 - 01/2005
10Adenosine Triphosphate (ATP)IBA
02/2021 - 06/2003
10KATP ChannelsIBA
12/2016 - 01/2004
9Pharmaceutical PreparationsIBA
01/2020 - 01/2002
9FormazansIBA
05/2008 - 01/2005
8DNA (Deoxyribonucleic Acid)IBA
09/2022 - 08/2013
8Messenger RNA (mRNA)IBA
01/2020 - 01/2003
8mitochondrial K(ATP) channelIBA
11/2010 - 06/2003
8kappa Opioid Receptors (kappa Opioid Receptor)IBA
08/2010 - 05/2004
7Aflatoxin B1 (Aflatoxin B)IBA
06/2018 - 07/2013
7norbinaltorphimineIBA
08/2010 - 05/2004
7(trans)-Isomer 3,4- Dichloro- N- methyl- N- (2- (1- pyrrolidinyl)- cyclohexyl)- benzeneacetamideIBA
08/2010 - 01/2003
7AtractylosideIBA
11/2009 - 01/2005
6Small Interfering RNA (siRNA)IBA
09/2022 - 08/2008
6LipopolysaccharidesIBA
01/2022 - 01/2005
6EnzymesIBA
01/2021 - 01/2002
6Reactive Oxygen Species (Oxygen Radicals)IBA
10/2017 - 06/2003
6AflatoxinsIBA
02/2016 - 01/2013
65-hydroxydecanoic acidIBA
11/2010 - 01/2004
6puerarinIBA
11/2010 - 03/2004
6Neuroprotective AgentsIBA
04/2010 - 05/2006
5AntioxidantsIBA
01/2022 - 02/2005
5alpha-Fetoproteins (alpha-Fetoprotein)IBA
08/2021 - 10/2009
5MicroRNAs (MicroRNA)IBA
11/2017 - 01/2013
5Glucose (Dextrose)FDA LinkGeneric
05/2015 - 05/2005
5Interleukin-2 (IL2)IBA
12/2006 - 01/2003
5Diazoxide (Hyperstat)FDA Link
07/2006 - 06/2003
5CalciumIBA
05/2004 - 01/2003
4Oxygen (Dioxygen)IBA
01/2021 - 05/2005
4Phosphotransferases (Kinase)IBA
01/2021 - 09/2007
4Antiviral Agents (Antivirals)IBA
08/2020 - 08/2014
4IntegrinsIBA
01/2018 - 08/2014
4Tacrolimus (Prograf)FDA LinkGeneric
05/2015 - 08/2004
4Superoxide DismutaseIBA
06/2013 - 01/2002
4triphenyltetrazoliumIBA
06/2013 - 01/2005
4Nitric Oxide Synthase (NO Synthase)IBA
01/2012 - 01/2005
4NG-Nitroarginine Methyl Ester (L-NAME)IBA
01/2012 - 02/2005
41- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
02/2010 - 02/2005
4SpermineIBA
07/2009 - 05/2006
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2006 - 06/2003
4NS 1619IBA
12/2005 - 01/2005
3LigandsIBA
03/2022 - 01/2019
3Retinaldehyde (Retinal)IBA
01/2022 - 01/2021
3Blood Glucose (Blood Sugar)IBA
11/2021 - 11/2011
3CholesterolIBA
11/2021 - 07/2017
3RNA (Ribonucleic Acid)IBA
01/2021 - 12/2014
3InterferonsIBA
01/2021 - 01/2014
3Acetaminophen (Paracetamol)FDA LinkGeneric
01/2021 - 01/2017
3Hormones (Hormone)IBA
01/2021 - 10/2015
3Toll-Like Receptors (Toll-Like Receptor)IBA
01/2020 - 06/2018

Therapy/Procedure

67Liver Transplantation
07/2022 - 08/2008
21Therapeutics
09/2022 - 02/2003
15Transplantation
07/2022 - 08/2004
14Ligation
01/2012 - 12/2002
7Hepatectomy
05/2022 - 12/2008
6Punctures
01/2012 - 12/2003
6Ischemic Postconditioning
08/2009 - 01/2007
4Drug Therapy (Chemotherapy)
01/2021 - 10/2009